GeNeuro is a clinical stage pharmaceutical company developing a new approach to the treatment of autoimmune diseases.
GeNeuro is a biotechnology company that develops therapeutic drugs for diseases associated with the expression of pathogenic proteins of the human endogenous retroviral origin.The company is primarily focused on nervous system diseases such as multiple sclerosis and schizophrenia. Its products include GNbAC1, a therapeutic monoclonal antibody for the treatment of multiple sclerosis. It also develops diagnostic tests to dose the multiple sclerosis-associated retrovirus-ENV proteins in patients.GeNeuro was founded in 2006 and is based in Plan-Les-Ouates, Switzerland.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
May 12, 2022 | Post-IPO Equity | €7.70M | 1 | — | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
Invesco | — | Post-IPO Equity |